Hair Loss & Regrowth — Peptide Research Overview
Androgenetic alopecia and other forms of hair loss have both well-established pharmaceutical treatments and emerging peptide-based approaches. The field spans FDA-approved DHT blockers and vasodilators through to copper peptides and growth factor modulators being studied for scalp rejuvenation.
Relevant Compounds
- GHK-Cu — Copper tripeptide studied for hair follicle stimulation, scalp inflammation reduction, and promotion of follicular keratinocyte proliferation.
- Finasteride — 5-alpha reductase type II inhibitor. FDA-approved for male pattern baldness. Reduces DHT conversion from testosterone.
- Dutasteride — Dual 5-alpha reductase inhibitor (types I and II). More potent DHT reduction than finasteride. Off-label for hair loss.
- Minoxidil — Vasodilator and potassium channel opener. FDA-approved topically for hair loss. Oral formulations used off-label at low doses.
What the Research Shows
GHK-Cu
[Preliminary / In Vitro] GHK-Cu stimulates hair follicle size and proliferation of dermal papilla cells in vitro. In small topical studies, it outperformed minoxidil in hair density metrics, though study quality is limited. It also reduces scalp DHT levels via modulation of 5AR enzymes in some in vitro models.
Finasteride
[Human Trial] Multiple Phase 3 RCTs demonstrate 1 mg/day finasteride produces meaningful hair regrowth or stabilization in ~85% of men with androgenetic alopecia over 2 years. DHT is reduced by ~70% at this dose. Long-term data (5+ years) shows continued efficacy with maintained use. FDA-approved as Propecia.
Dutasteride
[Human Trial] Dutasteride 0.5 mg/day reduces serum DHT by ~95% (vs. ~70% for finasteride). Head-to-head trials show superior hair count increases vs. finasteride. FDA-approved for BPH (Avodart); used off-label for hair loss. Side effect profile is similar to finasteride.
Minoxidil
[Human Trial] FDA-approved at 2% and 5% topical for both men and women. Prolongs the anagen (growth) phase and increases follicular size. Oral minoxidil 0.25–2.5 mg/day shows equivalent or superior results to topical in observational studies, with growing clinical use. Does not block DHT — often combined with finasteride for best results.
Evidence Summary
| Compound | Evidence Level | FDA Status |
|---|---|---|
| GHK-Cu | Preliminary / In Vitro | Not approved for hair loss |
| Finasteride | Human Trial (Phase 3) | Approved (Propecia — men only) |
| Dutasteride | Human Trial | Approved for BPH; off-label for hair loss |
| Minoxidil | Human Trial | Approved (topical); oral is off-label |
Research Disclaimer
GHK-Cu is not FDA-approved for hair loss. Finasteride and topical minoxidil are FDA-approved for specific indications only. Dutasteride and oral minoxidil are used off-label. This page is an educational summary of existing research. Consult your healthcare provider before using any compound.
Track your compounds with Dosi
Log doses, monitor symptoms, and build a personal health timeline. Free to start.
Start Tracking Free →Educational use only. This content is for informational purposes only and does not constitute medical advice. Individual results vary. Always consult a licensed healthcare provider before starting any compound.